JaxBio

Executive Summary

JaxBio is an Israeli preclinical biotech developing AI-driven, ultra-sensitive blood tests for early cancer detection. Its proprietary platform combines cell-free DNA (cfDNA) epigenetic pixel-pattern mapping with machine learning to identify multiple cancer types from a single blood draw, initially targeting lung cancer and hematological malignancies. Founded in 2020, the company has built a proprietary dataset and algorithm to detect cancer-specific methylation patterns, aiming to improve sensitivity and specificity over existing liquid biopsy approaches. JaxBio operates in a competitive space, but its focus on epigenetic patterns and AI differentiation positions it as a potential player in early oncology diagnostics. The company is currently preclinical, with no disclosed funding or valuation, but is actively advancing its technology toward clinical validation. If successful, JaxBio could address significant unmet needs in non-invasive cancer screening, particularly for high-risk populations.

Upcoming Catalysts (preview)

• Q1 2027Initiation of First-in-Human Clinical Trial for Lung Cancer Detection55% success
• Q4 2026Strategic Partnership or Co-Development Agreement with Diagnostic Company45% success
• Q3 2026Series B Funding Round to Support Clinical Development70% success